Related Experiment Video
Updated: May 5, 2026

Excitotoxic Stimulation of Brain Microslices as an In vitro Model of Stroke
Published on: February 4, 2014
Acute Treatment with Salvianolic Acid A Produces Neuroprotection in Stroke Models by Inducing Excitatory Long-Term
Jinnan Li1,2, Niya Wang1,2, Qi Huang3,4
1CAS Key Laboratory of Animal Models and Human Disease Mechanisms, KIZ-SU Joint Laboratory of Animal Model and Drug Development, Laboratory of Learning and Memory, Kunming Institute of Zoology, the Chinese Academy of Sciences, Kunming 650223, China.
Abstract:
Acute ischemic stroke (AIS) is a significant brain disease with a high mortality and disability rate. Additional therapies for AIS are urgently needed, and neuroplasticity mechanisms by agents are expected to be neuroprotective for AIS. As a major active component of Salvia miltiorrhiza, salvianolic acid A (SAA) has shown potential for preventing cardiovascular diseases. However, there is no evidence of the long-term effect of SAA on ischemic injury or its mechanism. Therefore, using rats and mice, we systematically investigated the impact of SAA on AIS from the perspective of neuroprotective and neuroplasticity. Here, we report that SAA induces a long-term depression (LTD)-like process in synapses. This antiexcitotoxicity action supports the SAA effect, including alleviating infarction and promoting blood circulation in photothrombosis and middle cerebral artery occlusion (MCAO) models. Furthermore, repeated positron emission tomography/computed tomography (PET/CT) imaging and behavioral assessments two months after AIS induction reveal that acute treatment of SAA promotes recovery from disrupted whole-brain glucose metabolism and impaired spatial memory. These data suggest that acute treatment of SAA is neuroprotective by improving long-term functional outcomes through a synaptic LTD-like process, providing a promising adjunct to current therapies to enable better recovery for AIS.
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Ischemic Stroke ll: Pathophysiology

